News overview

Oncode Concept Illustration On Green 07
7 November 2019
Oncode is hiring!
Interested in joining us? Oncode is an independent institute dedicated to understanding cancer and translating research into practice more efficiently. Oncode, starting from a deeper understanding of the basics of cancer, works to come up with better treatments and improved diagnostics.
Vesnade Jong
4 November 2019
A platform to fully exploit available clinical CRC studies
Miriam Koopman and Louis Vermeulen collaborate to improve prospects for colorectal cancer patients via Oncode's Equipment & Infrastructure Program. This program has a collaborative set-up to make equipment available throughout the community.
Foto Patientenavond
4 November 2019
Get the patient into the lab!
Oncode started the Patient Perspective Program. The goal of this program is to connect (ex-)patients to Oncode labs and/or individual Oncode researchers. This should decrease the distance between Oncode researchers and patients so they can explore, investigate and understand each other's worlds. Research groups from the Netherlands Cancer Institute and the LUMC are taking part in the first pilot of the Patient Perspective Program.
4 November 2019
Highlights of Oncode’s Glioblastoma Workshop
On October 16th 2019, Oncode held the second in the series of clinical workshops with the aim to strengthen the link between fundamental and clinical research.
Vesnade Jong
1 November 2019
TEIPP-targeting immunotherapy project funded by Oncode Institute
Oncode clinical Proof of concept Programme will fund the “TEIPP-targeting immunotherapy” project from Sjoerd van der Burg
Karin De Visser
28 October 2019
Inaugural lecture Karin de Visser
On Friday, 15 November 2019, Oncode Investigator Karin de Visser (NKI) will give her inaugural lecture (in Dutch) on the topic of Tumor Biology and Immunology with the title: 'The immune system: a double-edged sword that needs direction'. This event will take place at16.00 at the University of Leiden, (Academiegebouw, Rapenburg 73, 2311 GJ Leiden) and will be followed by a reception. The Oncode community is invited to be present at this ceremony.
Vesnade Jong
Oncode Icons Square 14
In the spotlight
27 September 2019
A cost-effective treatment strategy for metastatic colorectal carcinoma patients
The sustainability of the healthcare system is under extreme pressure, given the increasing costs associated with research, drug development, treatment and hospital care. Through support of its Investigators’ research and development activities, Oncode is working to advance new and innovative therapies to patients.
Vesnade Jong
Anne Rios 2
25 October 2019
Anne Rios receives the St. Baldrick’s Robert J. Arceci Innovation Award
Oncode Investigator Anne Rios of the Princess Máxima Center received the St. Baldrick’s Robert J. Arceci Innovation Award at the annual SIOP congress in Lyon, France. This is the first time the award has gone to the Netherlands.
Coverbeeld Q3
15 October 2019
Oncode Quarterly Magazine - October 2019
Welcome to the second edition of our quarterly magazine. Are you curious what kept us busy the past few months? In this edition you can read interviews with Jannie Borst, Andrea van Elsas, Ruben van Boxtel and Rebekka Schneider. And there's much more!
Vesnade Jong
11 October 2019
Geert Kops receives ERC Synergy Grant
Oncode's Scientific Director Geert Kops (Hubrecht Institute) has received a European Research Council (ERC) Synergy Grant to investigate the causes and effects of chromosomal aberrations in cancer, together with Iva Tolic (Ruder Boskovic Institute), Angelika Amon (Massachusetts Institute of Technology) and Nenad Pavin (University of Zagreb). Together they receive 10 million euros for their interdisciplinary effort that combines cell biology, bio(physics) and genetics.
Tumor Growth Theme
11 October 2019
The mutational impact of fluoropyrimidines
In their latest paper in Nature Communications, Oncode Investigator Edwin Cuppen and Arne van Hoeck (UMC Utrecht), together with colleagues, assess the mutational impact of fluoropyrimidines.